title: MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis).
abstract: Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc). Parkinsonian patients and animal models of PD show inflammatory phenomena such as microglial activation and cytokine production that could modulate the progression of the disease, since they play a crucial role in the degenerative process. Since acute phase proteins (APPs) are involved in a number of homeostatic alterations and inflammatory processes, we analyzed the levels of APPs in primates before and after treatment with MPTP. A significant increase in C-reactive protein (CRP), serum amyloid A (SAA) and haptoglobin (HP) levels after MPTP treatment. These results demonstrate that MPTP induces a systemic generalized inflammatory reaction after specific dopaminergic neurotoxicity insult, suggesting that the inflammatory process in Parkinsonism may affect other immune-inflammatory responses outside the brain.
authors.affiliation: Clinical and Experimental Neuroscience and Centro de Investigación Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), School of Medicine, University of Murcia, Campus de Espinardo, 30071 Murcia, Spain.
authors.forename: V
authors.initials: V
authors.lastname: De Pablos
authors.forename: C
authors.initials: C
authors.lastname: Barcia
authors.forename: S
authors.initials: S
authors.lastname: Martínez
authors.forename: A
authors.initials: A
authors.lastname: Gomez
authors.forename: F
authors.initials: F
authors.lastname: Ros-Bernal
authors.forename: J
authors.initials: J
authors.lastname: Zamarro-Parra
authors.forename: J J
authors.initials: JJ
authors.lastname: Soria-Torrecillas
authors.forename: J
authors.initials: J
authors.lastname: Hernández
authors.forename: J J
authors.initials: JJ
authors.lastname: Ceron
authors.forename: M T
authors.initials: MT
authors.lastname: Herrero
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000209:Acute-Phase Proteins / Q000378:metabolism*; D000818:Animals; D002097:C-Reactive Protein / Q000378:metabolism; D015259:Dopamine Agents; D006242:Haptoglobins / Q000378:metabolism; D007249:Inflammation / Q000097:blood; D008252:Macaca fascicularis; D008297:Male; D010302:Parkinson Disease, Secondary / Q000097:blood / Q000139:chemically induced / Q000276:immunology*; D000685:Serum Amyloid A Protein / Q000378:metabolism
chemical_list: D000209:Acute-Phase Proteins; D015259:Dopamine Agents; D006242:Haptoglobins; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine